{
    "clinical_study": {
        "@rank": "50461", 
        "arm_group": [
            {
                "arm_group_label": "patients who undergo RP plus photofrin-based PDT", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "patients who undergo RP alone", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized Phase II trial to test whether the addition of intraoperative\n      Photofrin-mediated photodynamic therapy to radical pleurectomy and post-operative\n      chemo.improves OS in the treatment of patients with epithelioid MPM. Subjects assigned to\n      the PDT arm will be given the photosensitizer prior to surgery . All subjects will receive\n      maximal surgical debulking. Subjects in the PDT arm will receive intraoperative treatment\n      using real-time, isotropic light dosimetry."
        }, 
        "brief_title": "MPM PDT Phase II Trial", 
        "completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Epitheliod Malignant Pleural Mesothelioma", 
        "condition_browse": {
            "mesh_term": "Mesothelioma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a histologic diagnosis of MPM, epithelioid subtype, who in the opinion\n             of the attending thoracic surgeon can receive a macroscopically complete resection of\n             tumor.\n\n          -  Patients must have disease limited to the hemithorax.\n\n          -  Patients who have received prior surgery, gene therapy, or combination chemotherapy\n             will be permitted if it has been at least 30 days since the last treatment.\n\n          -  Subjects treated with pemetrexed previously will be eligible only if 8 weeks have\n             elapsed between the last dose of pemetrexed and the date of surgery.\n\n          -  ECOG performance status of 0-1. Medical suitability for resection,including\n             documented medical and cardiac clearance.\n\n          -  18 years of age or older. Patients must sign a document that indicates that they are\n             aware of the investigative nature of the treatment of this protocol, and the\n             potential benefits and risks.\n\n          -  Patients unwilling or unable due to cognitive impairment to sign informed consent are\n             excluded from the study.\n\n        Exclusion Criteria:\n\n          -  Patients with active invasive cancers, other than MPM, that require additional\n             treatment, except nonmelanomatous skin cancer, superficial bladder or cervical\n             cancer, and early-stage prostate cancer.\n\n          -  Pregnant or lactating patients. Patients who have a history of HIV disease. -\n             Patients who have a white count less than 2,500 per cubic mm or platelets less than\n             100,000/cubic mm. Serum creatinine equal or greater than 2.5 mg/deciliter. -\n\n          -  Patients who have severe liver disease including cirrhosis, Grade III-IV elevations\n             in liver function studies, or bilirubin in excess of 1.5 mg/deciliter. -\n\n          -  Patients with porphyria or hypersensitivity to porphyrin or porphyrin-like compounds.\n\n          -  Patients who have been treated with pemetrexed if the last dose of pemetrexed is 8\n             weeks to the date of surgery. -\n\n          -  Patients that have been treated with prior Mantle field radiation. Patients with\n             distant metastatic disease or otherwise not confined to the ipsilateral hemithorax."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153229", 
            "org_study_id": "UPCC 14513"
        }, 
        "intervention": [
            {
                "arm_group_label": "patients who undergo RP plus photofrin-based PDT", 
                "intervention_name": "Photodynamic Therapy", 
                "intervention_type": "Radiation", 
                "other_name": "PDT"
            }, 
            {
                "arm_group_label": [
                    "patients who undergo RP plus photofrin-based PDT", 
                    "patients who undergo RP alone"
                ], 
                "intervention_name": "Radical Pleurectomy", 
                "intervention_type": "Procedure", 
                "other_name": "RP"
            }, 
            {
                "arm_group_label": [
                    "patients who undergo RP plus photofrin-based PDT", 
                    "patients who undergo RP alone"
                ], 
                "intervention_name": "Chemotherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "patients who undergo RP plus photofrin-based PDT", 
                "description": "If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy", 
                "intervention_name": "Photofrin 2.0 mg/kg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Trioxsalen", 
                "Dihematoporphyrin Ether", 
                "Hematoporphyrin Derivative"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Histological diagnosis of MPM", 
            "epitheliod subtype", 
            "limited to the hemithorax", 
            "macroscopically complete resection of the tumor"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Michele.Cooper@RoswellPark.org", 
                    "last_name": "Michele Cooper, RN", 
                    "phone": "716-845-4427"
                }, 
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263"
                    }, 
                    "name": "Rosewell Park"
                }, 
                "investigator": {
                    "last_name": "Todd Demmy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Sally.McNulty@uphs.upenn.edu", 
                    "last_name": "Sally McNulty, RN", 
                    "phone": "215-662-7720"
                }, 
                "contact_backup": {
                    "email": "PennCancerTrials@emergingmed.com", 
                    "last_name": "Keith Cengel, MD, PhD", 
                    "phone": "855-216-0098"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Abramson Cancer Center of the University of Pennsylvania"
                }, 
                "investigator": {
                    "last_name": "Keith Cengel, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized Phase 2 Trial of Radical Pleurectomy and Post-Operative Chemotherapy With or Without Intraoperative Porfimer Sodium -Mediated Photodynamic Therapy for Patients With Epitheliod Malignant Pleural Mesothelioma", 
        "overall_contact": {
            "email": "Sally.Mcnulty@uphs.upenn.edu", 
            "last_name": "Sally McNulty, RN", 
            "phone": "215-662-7720"
        }, 
        "overall_official": {
            "affiliation": "Abramson Cancer Center of the University of Pennsylvania", 
            "last_name": "Keith Cengel, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153229"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abramson Cancer Center of the University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}